/
Immunology
Systemic Lupus Erythematosus
121
Pipeline Programs↗
180
Active Trials↗
100
Companies Involved↗
Systemic Lupus Erythematosus is a highly competitive landscape with 121 programs across 100 companies. The most active players are AstraZeneca, Bristol-Myers Squibb, GSK. 17 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical28
Phase 148
Phase 228
Phase 317
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
68 of 97 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 97 classified programs, each share of the total. Modality classified for 91% of 121 pipeline programs.
Analysis
Trial Status
462
clinical trials
Completed191 · 41%
Recruiting101 · 22%
Terminated43 · 9%
Not yet recruiting37 · 8%
Active, not recruiting37 · 8%
Unknown status29 · 6%
Other24 · 5%
Clinical Trials
Trial Activity
462 trials
Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)
Recruiting·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·N/A·NCT00001372·2,000 enrolled
Page 1 of 31
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)